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Abstract
Introduction: Numerous pathogenic mutations responsible for mitochondrial diseases have been identified in
mitochondrial DNA (mtDNA)-encoded tRNA genes. In most cases, however, the detailed molecular
pathomechanisms and cellular pathophysiology of these mtDNA mutations —how such genetic defects determine
the variation and the severity of clinical symptoms in affected individuals— remain unclear. To investigate the
molecular pathomechanisms and to realize in vitro recapitulation of mitochondrial diseases, intracellular mutant
mtDNA proportions must always be considered.
Results: We found a disease-causative mutation, m.5541C>T heteroplasmy in MT-TW gene, in a patient exhibiting
mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with multiple organ
involvement. We identified the intrinsic molecular pathomechanisms of m.5541C>T. This mutation firstly disturbed
the translation machinery of mitochondrial tRNATrp and induced mitochondrial respiratory dysfunction, followed by
severely injured mitochondrial homeostasis. We also demonstrated cell-type-specific disease phenotypes using
patient-derived induced pluripotent stem cells (iPSCs) carrying ~100 % mutant m.5541C>T. Significant loss of
terminally differentiated iPSC-derived neurons, but not their stem/progenitor cells, was detected most likely due to
serious mitochondrial dysfunction triggered by m.5541C>T; in contrast, m.5541C>T did not apparently affect skeletal
muscle development.
Conclusions: Our iPSC-based disease models would be widely available for understanding the "definite" genotype-
phenotype relationship of affected tissues and organs in various mitochondrial diseases caused by heteroplasmic
mtDNA mutations, as well as for further drug discovery applications.
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Introduction
Mitochondrial DNA (mtDNA) has unique translation
and transcription machinery and is associated with the
maintenance of cellular homeostasis through interge-
nomic crosstalk with nuclear DNA (nDNA). Numerous
pathogenic mutations responsible for various mitochon-
drial diseases have been identified in mtDNA-encoded
tRNA genes [1], and in most cases, such disease-causa-
tive heteroplasmic mutations (i.e., wild-type mtDNA and
mutant mtDNA co-exist within a cell) exhibit their intrin-
sic pathogenic thresholds. Mutant mitochondrial tRNAs
frequently induce various loss-of-function at a molecular
level [2] including not only damaged mitochondrial pro-
tein synthesis, but also inhibited aminoacylation [3], tRNA
molecular instability [4], altered tRNA processing [5],
wobble-base modification deficiency [6, 7], or a combin-
ation of these. Therefore, the degree of accumulated mu-
tant mitochondrial tRNAs within a cell is most likely to
determine the trajectory of tissue- and organ-specific dis-
ease progression and phenotypic severity in affected indi-
viduals. Focusing on MT-TW gene, which encodes
mitochondrial tRNATrp, several pathogenic mutations have
been reported to cause widespread clinical symptoms in rela-
tion to mitochondrial diseases (e.g., encephalopathy, myopathy,
dementia and chorea, gastrointestinal syndrome, or severe
multiple organ disorders) [8–13].
Mitochondrial myopathy, encephalopathy, lactic
acidosis, and stroke-like episodes (MELAS) is genetic-
ally heterogeneous and presents a broad clinical
spectrum among individuals [14] including variations
in age of onset (infantile to adolescence) or affected
tissues and organs (central nervous system, cardiovas-
cular system, neuromuscular system, endocrine sys-
tem, gastrointestinal system, or a combination of
these). Such variations may depend on the influence
of molecular defects in mitochondrial respiratory
chain complexes I and/or IV (CI and/or CIV) on
mitochondrial energy metabolism and oxidative stress
in various terminally differentiated cell types in af-
fected individuals. To date, however, limited somatic
cell types (e.g., fibroblasts, myoblasts, or lymphoblasts)
are available to characterize patient-specific patho-
physiology of affected tissues and organs in mitochon-
drial diseases. Recently, the generation of induced
pluripotent stem cells (iPSCs) from various human
somatic cells by forced ectopic expression of several
pluripotency-associated transcription factors has been
reported [15, 16], and patient-derived iPSCs carrying
mutant mtDNAs have therefore opened new avenues
for facilitating mitochondrial medicine.
In this study, we found a disease-causative muta-
tion, m.5541C > T heteroplasmy in MT-TW gene, in a
patient exhibiting MELAS with multiple organ in-
volvement. We identified the intrinsic molecular
pathomechanisms of m.5541C > T and demonstrated
cell-type-specific disease phenotypes using patient-
derived iPSCs carrying ~100 % mutant m.5541C > T.
Our iPSC-based disease models would be widely
available for understanding the definitive genotype-
phenotype relationship of affected tissues and organs
in various mitochondrial diseases caused by hetero-




This study was approved by our Institutional Review
Board and was stringently conducted in accordance with
the ethical principles of the "Declaration of Helsinki".
Patient biopsy was performed for diagnostic purposes
only after we received written informed consent with
permission to study patient-derived iPSCs. Note that 10
control subjects were also used in this study.
A partial family pedigree for this patient is shown
(Fig. 1a). In this family, there was no clinical history of
any neuromuscular disease. He had no growth and men-
tal retardation until firstly presenting epileptic symptoms
at age 10 years. At age 11 years, he developed weight
loss, activity loss, easy fatigue, cognitive impairment, and
acute heart failure. Radiographic and ultracardiographic
images revealed hypertrophic cardiomyopathy at inter-
ventricular septum and left ventricular wall (Fig. 1b).
Markedly increased serum lactate level (114.7 mg/dL;
3.0-17.0 mg/dL as normal), serum pyruvate level
(3.86 mg/dL; 0.30–0.94 mg/dL as normal), and lactate/
pyruvate ratio (29.7) were detected. At age 13 years, he
developed headache, vomiting, visual disturbance, con-
vulsion, and myoclonic status with unconsciousness.
Brain MRI revealed multifocal hyper-intensity lesions at
basal ganglia, cortex, and subcortical white matter of
both cerebrum and cerebellum. A representative lesion
showed decreased N-acetylaspartate level and increased
lactate level (Fig. 1c). On this occasion, no significant ab-
normalities in serum lactate level (18.9 mg/dL), serum
pyruvate level (0.99 mg/dL), or lactate/pyruvate ratio
(19.0) were detected; however, cerebrospinal fluid lactate
level (41.5 mg/dL), cerebrospinal fluid pyruvate level
(1.40 mg/dL), and lactate/pyruvate ratio (29.6) were
clearly high. Skeletal muscle histopathology revealed dif-
fuse cytochrome c oxidase (COX) deficiency (less than
5 % population of COX-positive fibers) (Fig. 1d); how-
ever, no other typical pathological abnormalities such as
ragged-red-fibers or strongly succinate dehydrogenase
(SDH)-reactive blood vessels were observed. We diag-
nosed this patient as MELAS and started oral administra-
tion of l-arginine, dichloroacetate, and sodium pyruvate.
He relapsed with stroke-like episodes twice in 4 years. At
age 14 years, he developed multiple organ involvement
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including acute pancreatitis, gastrointestinal malabsorp-
tion, renal tubular disturbance, and endocrine glucose in-
tolerance. At age 15 years, he developed quadriparesis.
Now, he keeps stable condition without serious trouble.
Myoblast culture
Patient-derived skeletal muscle tissues were minced,
enzymatically digested, and centrifuged to collect myo-
blasts according to standard protocol. Patient-derived
myoblasts were maintained in DMEM/F12 (Gibco) sup-
plemented with 20 % FBS (Gibco), 100 units/mL penicil-
lin (Gibco), 100 μg/mL streptomycin (Gibco) at 37 °C
under humidified atmosphere of 5 % CO2. During estab-
lishment of patient-derived primary myoblasts, 0.5 μg/
mL MC210 (DS Pharm) as a mycoplasmacidal reagent
and 2.5 μg/mL fungizone (Gibco) as a fungicidal reagent
were also added to culture medium.
Terminal differentiation of patient-derived myoblasts
into myotubes was performed as follows: Briefly, patient-
derived myoblasts were seeded at high cell density onto
6-well culture plates and were maintained at 37 °C under
humidified atmosphere of 5 % CO2. After 3 days in
culture, culture medium was switched to myogenic
differentiation medium (Cell Applications) supple-
mented with 100 units/mL penicillin (Gibco), 100 μg/mL
streptomycin (Gibco), and patient-derived myoblasts
were maintained at 37 °C under humidified atmosphere
of 5 % CO2 for 2 weeks.
Analysis of mtDNA mutation
Long PCR-based whole mtDNA sequencing for the
patient was performed as described elsewhere [17] with
modifications to eliminate any adverse results arising
from pseudo-sequences in nuclear DNA: Briefly, ex-
tracted DNA as template (10 ng for iPSCs, 20 ng for
myoblasts and skeletal muscle tissues, 100 ng for blood
tissues) was amplified via mtDNA-specific long-range
PCR and the following mtDNA-specific nested PCR with
a thermal cycler (GeneAmp PCR System 9700; Applied
Biosystems). The amplified mtDNA fragments were se-
quenced with a DNA analyzer (ABI PRISM 3130xl; Ap-
plied Biosystems). The obtained mtDNA sequence data
from each patient was compared with the databases of
"Human Mitochondrial Genome Database (MITOMAP;
http://www.mitomap.org/MITOMAP/)" and "Human
Mitochondrial Genome Polymorphism (mtSNP; http://
mtsnp.tmig.or.jp/mtsnp/)" [18] to find any genetic
variants.
Mutation ratio of m.5541C > T in the patient was
determined as follows: Extracted DNA (1 ng) was
used as template for quantitative PCR with TaqMan
Universal PCR Master Mix kit (Applied Biosystems)
according to the manufacturer’s instructions. A se-
quence detection system (ABI PRISM 7900HT; Ap-
plied Biosystems) was used, and a calibration curve
was created using several copy-number standards
with plasmids containing the amplified mtDNA frag-
ments (nucleotide position in mtDNA; 5205–5767)
for either wild-type or mutant sequences.
Protein and tRNA modeling
in silico modeling of bovine heart CIV homodimer in
fully oxidized state [19] was performed on the database of
"RCSB Protein Data Bank (http://www.rcsb.org/pdb/)",
and the graphics were arranged using RasMol software.
Amino acid sequences of bovine and human mtDNA-
encoded CIV subunits were referenced in the database of
"NCBI Protein Database (http://www.ncbi.nlm.nih.gov/
protein/)".
in silico modeling of wild-type and mutant mitochon-
drial tRNATrp were performed on the database of "Vienna
RNA Servers (http://rna.tbi.univie.ac.at/)", and representa-
tive physicochemical parameters (e.g., minimum free
energy and base-pair probability) were simultaneously
calculated.
Reverse transcription PCR (RT-PCR) and quantitative PCR
Reverse transcription was performed with PrimeScript
RT Master Mix kit (TaKaRa Bio) according to the manu-
facturer’s instructions. After reverse transcription of
extracted total RNA, total cDNA (25 ng) was used as
template for RT-PCR with a thermal cycler (GeneAmp
PCR system 9700; Applied Biosystems). The amplified
PCR products were resolved via electrophoresis through
2 % agarose gel, stained with GelGreen (Biotium), and
detected with a UV transilluminator (GelDoc-It Imaging
System; UVP).
(See figure on previous page.)
Fig. 1 Clinical diagnosis and molecular genetic analysis for the patient. a A partial family pedigree. Filled square indicates this patient. b
Radiographic and ultracardiographic images for this patient at age 11 years, indicating hypertrophic cardiomyopathy. Cardiothoracic ratio (CTR) in
radiographic image is also shown. c T2-weighted FLAIR images of brain MRI for this patient at age 13 years, indicating multifocal stroke-like
episodes. Brain MRS also shows decreased N-acetylaspartate (NAA) level and increased lactate (Lac) level. d Histopathology against serial frozen
sections of biopsied skeletal muscle specimens from this patient at age 13 years, indicating diffuse COX deficiency. e Electropherograms of the
anticodon domain of MT-TW gene for extracted DNA from blood tissues and skeletal muscle tissues of both control and this patient. Arrowheads
indicate m.5541C > T. Note that the same mutation was also found in blood tissues from this patient’s asymptomatic mother. f Alignment of
sequences in the anticodon-stem and the anticodon-loop of MT-TW gene from various eukaryotes. Arrowhead indicates m.5541C > T.
Blue-colored characters indicate the anticodon recognition site of mitochondrial tRNATrp
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Quantitative PCR for measurement of transgenes ex-
pression was performed with SYBR Green I PCR Master
Mix kit (Roche) according to the manufacturer’s instruc-
tions. After reverse transcription of extracted total RNA,
total cDNA (10 ng) was used as template for quantitative
PCR with a real-time PCR system (LightCycler 480II;
Roche). The averaged threshold cycle number for
housekeeping genes were adopted for ΔΔCT-based rela-
tive quantification.
Analysis of mitochondrial enzymatic activity
Enzymatic activities for individual mitochondrial re-
spiratory chain complexes were analyzed as described
elsewhere [20] with modifications: Cultured and
Fig. 3 Generation of disease-relevant iPSCs carrying all mutant mitochondrial tRNATrp. a Representative images of the established iPSC lines; OCT4
(red), NANOG (red), TRA-1-60 (green), TRA-1-81 (green). Arrowheads in electropherograms indicate m.5541C > T. b Representative images of the
embryoid body (EB)-mediated in vitro spontaneous differentiation into three germ layers; TUJ1 (ectoderm, red), αSMA (mesoderm, red), AFP
(endoderm, red). c Expression of other representative pluripotency genes in the established iPSC lines. d Silencing of transgenes expression in the
established iPSC lines. Parental myoblasts after 7 days of transduction were also used as positive samples for both control and the patient.
Expression level of each transgene was calculated using ΔΔCT-based relative quantification method by real-time PCR. Measurements were
performed in triplicate. ND: Not Detected
(See figure on previous page.)
Fig. 2 Mutant mitochondrial tRNATrp triggers widespread mitochondrial dysfunction. a Enzymatic activities of individual mitochondrial respiratory
chain complexes for cultured myoblasts of both controls (n = 10, closed circles) and the patient (open circles). Error bars indicate as the means
with SD of controls. All samples were measured in triplicate and averaged. b Representative images of cytochemical staining of COX and SDH for
cultured myoblasts from both controls and the patient. Cell nuclei were co-stained with hematoxylin. c,d Immunodetection of c individual
respiratory chain complexes and d respiratory chain supercomplexes for isolated mitochondria from cultured myoblasts of both controls and the
patient. e Gene expression of several CIV structural subunits for extracted mRNA from cultured myoblasts of both controls and the patient. f
Protein expression of several CIV structural subunits for isolated mitochondria from cultured myoblasts of both controls and the patient. g
Representative images of immunocytochemical staining of CIV structural subunits for cultured myoblasts of both controls and the patient; MT-
CO1 (red), COX4 (red). Mitochondria were co-stained with MitoTracker (green). h ATP level for cultured myoblasts of both controls (n = 10,
closed circles) and the patient (open circles). Error bar indicates as the mean with SD of controls. All samples were measured in triplicate and
averaged. i Oxidative stress level for cultured myoblasts of both controls (n = 10, closed circles) and the patient (open circle). Fluorescence
intensity ratio of MitoSOX/MitoTracker served as mitochondrial ROS level. Error bar indicates as the mean with SD of controls. All samples were
measured in triplicate and averaged. j Membrane potential (ΔΨm) level for cultured myoblasts of both controls (n = 10, closed circles) and the
patient (open circle). Fluorescence intensity ratio of JC-1 dye aggregates/monomers served as mitochondrial ΔΨm level. Error bar indicates as
the mean with SD of controls. All samples were measured in triplicate and averaged
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Fig. 4 Mutant mitochondrial tRNATrp strongly impairs neuronal maturation, but does not affect skeletal muscle development. a Experimental
design used to identify patient-specific disease phenotypes triggered by m.5541C > T. b Representative images of myotubes after 2 weeks of
differentiation; ACTA1 (red). Cell nuclei were co-stained with Hoechst 33342 (blue). c Differentiation efficiency of myoblasts into myotubes. The
number of ACTA1-positive myotubes was counted using a cytometer to estimate differentiation efficiency. Assays were performed using 3
experimental replicates for both control and the patient. Error bars indicate as the means with SD. Statistical significance was evaluated
by unpaired, two-tailed t-test. NS: Not Significant. d Representative images of iPSC-derived NSCs; Nestin (green). e Expression of
representative NSC marker genes in iPSC-derived NSCs. f Representative images of CNS neurons after 2 weeks of differentiation; TUJ1
(red). Cell nuclei were co-stained with Hoechst 33342 (blue). g Differentiation efficiency of NSCs into CNS neurons. The number of
TUJ1-positive CNS neurons was counted using a cytometer to estimate differentiation efficiency. Assays were performed using 3
experimental replicates for both control and the patient. Error bars indicate as the means with SD. Statistical significance was evaluated
by unpaired, two-tailed t-test. *: P < 0.05. h Representative images of iPSC-derived NCCs; HNK1 (green). i Expression of representative NCC
marker genes in iPSC-derived NCCs. j Representative images of PNS neurons after 2 weeks of differentiation;
Peripherin (red). Cell nuclei were co-stained with Hoechst 33342 (blue). k Differentiation efficiency of NCCs into PNS neurons. The number
of Peripherin-positive PNS neurons was counted using a cytometer to estimate differentiation efficiency. Assays were performed using 3
experimental replicates for both control and the patient. Error bars indicate as the means with SD. Statistical significance was evaluated
by unpaired, two-tailed t-test. *: P < 0.05
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harvested patient-derived myoblasts (1 × 105 cells/
assay) were applied for measurement. A spectropho-
tometer equipped with thermostated unit (U-2010;
Hitachi) was used, and a base line calibration was
done before each measurement.
For CI activity measurement, cells were added into
reaction buffer [pH 7.4; 50 mM Tris–HCl, 250 mM
sucrose, 1 mM EDTA, 10 μM decylubiquinone, 50 μM
NADH, 5 μg/mL antimycin A, 2 mM potassium cyan-
ide] and were incubated at 37 °C. CI activity was moni-
tored by time-dependent absorbance alterations.
For CII activity measurement, cells were added into
reaction buffer [pH 7.4; 50 mM potassium phosphate,
20 mM succinate, 50 μM 2,6-dichlorophenolindophenol,
50 μM decylubiquinone, 5 μg/mL rotenone, 5 μg/mL
antimycin A, 2 mM potassium cyanide] and were in-
cubated at 37 °C. CII activity was monitored by time-
dependent absorbance alterations.
For CIII activity measurement, cells were added into
reaction buffer [pH 7.4; 50 mM Tris–HCl, 250 mM su-
crose, 1 mM EDTA, 50 μM cytochrome c, 50 μM decy-
lubiquinol (reduced form of decylubiquinone), 2 mM
potassium cyanide] and were incubated at 37 °C. CIII ac-
tivity was monitored by time-dependent absorbance
alterations.
For CIV activity measurement, cells were added into re-
action buffer [pH 7.4; 10 mM potassium phosphate, 25 μM
ferrocytochrome c (reduced form of cytochrome c)] and
were incubated at 37 °C. CIV activity was monitored by
time-dependent absorbance alterations.
For citrate synthase (CS) activity measurement, cells
were added into reaction buffer [pH 8.0; 125 mM Tris–
HCl, 300 μM acetyl-CoA, 100 μM 5,5’-dithiobis (2-nitro-
benzoic acid), 500 μM oxaloacetate] and were incubated
at 37 °C. CS activity was monitored by time-dependent
absorbance alterations.
Electrophoretic separation of mitochondrial proteins
Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) [21] and blue native polyacryl-
amide gel electrophoresis (BN-PAGE) [22] were
performed as described elsewhere with modifications,
respectively: Cultured and harvested patient-derived
myoblasts were resuspended in isolation buffer
[pH 7.4; 210 mM mannitol, 70 mM sucrose, 1 mM
EGTA, 5 mM HEPES] and were homogenated on
ice. Cell lysates were centrifuged to isolate mito-
chondrial proteins. Obtained mitochondrial proteins
were quantified by Bradford assay, and a calibration
curve was created using several known concentra-
tions of BSA.
For SDS-PAGE, isolated mitochondrial proteins (100 μg)
were solubilized with 0.5 % SDS containing 50 mM dithio-
threitol at 70 °C for 10 min. Electrophoresis was performed
on 4 –12 % NuPAGE polyacrylamide gel (Invitrogen) at
room temperature under 200 V constant.
For BN-PAGE, isolated mitochondrial proteins
(100 μg) were solubilized with either 0.5 % n-dodecyl-β-
d-maltoside (individual complexes detection) or 1 % dig-
itonin (supercomplexes detection) on ice for 30 min.
Insoluble proteins were removed by centrifugation.
Electrophoresis was performed on 3 –12 % NativePAGE
polyacrylamide gel (Invitrogen) at 4 °C under 150 V con-
stant for 30 min, then resumed at 4 °C under 250 V
constant.
Western blot for immunodetection of mitochondrial
proteins
Electrophoresed gels were blotted onto polyvinylidene
fluoride (PVDF) membranes using an iBlot transfer system
(Invitrogen) according to the manufacturer’s instructions.
Blotted PVDF membranes were blocked at room
temperature for 30 min. Primary antibody probing was per-
formed at room temperature for 90 min. Secondary anti-
body probing was performed with chromogenic antibody
detection kit (WesternBreeze; Invitrogen) according to the
manufacturer’s instructions. Primary antibodies used for
SDS-PAGE were as follows: 0.5 μg/mL anti-porin (Molecu-
lar Probes), 2.5 μg/mL anti-MT-CO1 (Molecular Probes),
2.5 μg/mL anti-MT-CO2 (Molecular Probes), 2.5 μg/mL
anti-COX4 (Molecular Probes), 2.5 μg/mL anti-COX5B
(Molecular Probes). Primary antibodies used for BN-PAGE
were as follows: 0.5 μg/mL anti-NDUFA9 for CI (Molecular
Probes), 0.5 μg/mL anti-SDHA for CII (Molecular Probes),
0.5 μg/mL anti-UQCRC2 for CIII (Molecular Probes),
2.5 μg/mL anti-MT-CO1 for CIV (Molecular Probes),
0.5 μg/mL anti-ATP5B for CV (Molecular Probes).
Cytochemical staining
Patient-derived myoblasts were seeded onto 4-well cul-
ture slides and were maintained at 37 °C under humidi-
fied atmosphere of 5 % CO2. After 3 days in culture,
cytochemical staining was performed as follows:
For cytochemical COX staining, cells were stained
with reaction buffer [pH 5.5; 100 mM sodium acetate,
0.1 % MnCl2, 0.001 % H2O2, 10 mM diaminobenzidine]
at 37 °C for 1 h, followed by subsequent incubation
with 1 % CuSO4 at 37 °C for 5 min. Cell nuclei were
co-stained with hematoxylin. Stained cells were rinsed,
fixed, and dehydrated according to standard histological
protocol. Samples were sealed with cover glass and were
observed under an optical microscope (BX50 System;
Olympus).
For cytochemical SDH staining, cells were stained with
reaction buffer [pH 7.4; 50 mM succinate, 1 mM nitrote-
trazolium blue] at 37 °C for 1 h. Cell nuclei were co-
stained with hematoxylin. Stained cells were rinsed,
fixed, and dehydrated according to standard histological
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protocol. Samples were sealed with cover glass and were
observed under an optical microscope (BX50 System;
Olympus).
Immunocytochemical detection of CIV structural subunits
Patient-derived myoblasts were seeded onto 4-well cul-
ture slides and were maintained at 37 °C under humidi-
fied atmosphere of 5 % CO2. After 3 days in culture,
cells were fixed, permeabilized, and blocked according to
standard immunocytochemical protocol. Primary anti-
body probing was performed at room temperature for
2 h. Secondary antibody probing was performed with
2.5 μg/mL Alexa Fluor 568 (Molecular Probes) at room
temperature for 1 h. Mitochondria were co-stained with
0.25 μg/mL MitoTracker Green (Molecular Probes).
Stained cells were observed under a fluorescent micro-
scope (IX71 System; Olympus). Primary antibodies used
were as follows: 2.5 μg/mL anti-MT-CO1 (Molecular
Probes), 2.5 μg/mL anti-COX4 (Molecular Probes).
Analysis of ATP level
Cultured and harvested patient-derived myoblasts (100
cells/assay) were applied for measurement. ATP amount
was monitored with rLuciferase/Luciferin chemilumines-
cence-based ATP detection kit (Promega) according to the
manufacturer’s instructions. A chemiluminescent multi-
well plate reader (Centro LB 960; Berthold Technologies)
was used, and a calibration curve was created using several
known concentrations of ATP.
Analysis of oxidative stress level and membrane potential
level
Patient-derived myoblasts were seeded onto 96-well cul-
ture plate and were maintained at 37 °C under humidi-
fied atmosphere of 5 % CO2. After 3 days in culture,
cells were stained at 37 °C for 1 h. Stained cells were
rinsed and were measured on a fluorescent multi-well
plate reader (ARVO SX; Perkin Elmer); first at excita-
tion/emission of 545/595 nm (red fluorescence) and then
sequentially at excitation/emission of 485/535 nm (green
fluorescence). Fluorescent dyes used were as follows:
0.25 μg/mL MitoTracker Green (Molecular Probes),
0.25 μg/mL MitoSOX Red (Molecular Probes), 0.25 μg/mL
JC-1 (Molecular Probes).
Generation of patient-derived iPSCs with episomal vector
Patient-derived iPSCs were generated using episomal
vectors as described previously [23] with modifications:
Briefly, each 1 μg of episomal plasmid vectors (Plasmid
#27077, #27078, #27080; Addgene) were electroporated
into patient-derived myoblasts (5 × 105 cells) with an
electroporator (Neon; Invitrogen). Transformed patient-
derived myoblasts (1 × 105 cells) were reseeded onto
mouse embryonic fibroblasts (MEF; ReproCELL) 4 days
after electroporation. The next day, culture medium was
replaced with primate ESC culture medium (Repro-
CELL) supplemented with 10 ng/mL bFGF (Repro-
CELL), 100 units/mL penicillin (Gibco), 100 μg/mL
streptomycin (Gibco), and transformed patient-derived
myoblasts were maintained at 37 °C under humidified
atmosphere of 5 % CO2. Emergent colonies with ESC-
like morphology were manually picked up to establish
patient-derived iPSCs, and these iPSCs were expanded
either on MEF-seeded dishes in primate ESC culture
medium or on Geltrex (Gibco)-coated dishes in mTeSR1
medium (STEMCELL Technologies) supplemented with
100 units/mL penicillin (Gibco), 100 μg/mL strepto-
mycin (Gibco) for long-term maintenance.
Characterization of patient-derived iPSCs
Characterization of patient-derived iPSCs via detection
of pluripotency markers was performed as follows:
Briefly, cultured and harvested patient-derived iPSCs
were transferred onto MEF-seeded 6-well culture plates
and were maintained in primate ESC culture medium at
37 °C under humidified atmosphere of 5 % CO2. After
3 days in culture, patient-derived iPSCs were character-
ized by immunocytochemical staining. Fluorophore-
conjugated primary antibodies used were as follows:
5 μg/mL Cy3-conjugated anti-OCT4 (Millipore), 5 μg/
mL Cy3-conjugated anti-NANOG (Millipore), 5 μg/mL
AlexaFluor 488-conjugated anti-TRA-1-60 (Millipore),
5 μg/mL AlexaFluor 488-conjugated anti-TRA-1-81
(Millipore).
in vitro spontaneous differentiation of patient-derived
iPSCs into EB-mediated three germ layers was per-
formed as follows: Briefly, cultured and harvested
patient-derived iPSCs were transferred onto ultra-low-
adherent culture dishes (HydroCell; CellSeed) and were
maintained in primate ESC culture medium without
bFGF at 37 °C under humidified atmosphere of 5 %
CO2. After 7 days in floating culture, emergent EBs were
transferred onto gelatin-coated 6-well culture plates and
were maintained in primate ESC culture medium with-
out bFGF at 37 °C under humidified atmosphere of 5 %
CO2. After 14 additional days in adherent culture,
spontaneously differentiated cells were characterized by
immunocytochemical staining. Primary antibodies used
were as follows: 5 μg/mL anti-TUJ1 for ectoderm
(Abcam), 5 μg/mL anti-αSMA for mesoderm (Abcam),
5 μg/mL anti-AFP for endoderm (Abcam). Secondary
antibody used was 2.5 μg/mL Alexa Fluor 568 (Molecular
Probes).
Directed differentiation of iPSCs into neural stem cells
(NSCs)
Directed differentiation of patient-derived iPSCs into
NSCs was performed according to a previous report
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[24] with modifications: Briefly, patient-derived iPSCs
were seeded onto Geltrex-coated dishes and were
maintained in mTeSR1 medium at 37 °C under hu-
midified atmosphere of 5 % CO2. After 3 days in ad-
herent culture, culture medium was switched to NSC
induction medium [1:1 mixture of DMEM/F12
(Gibco) and Neurobasal medium (Gibco) supple-
mented with 1 × N2 (Gibco), 1 × B27 minus vitamin A
(Gibco), 1 × GlutaMAX (Gibco), 100 units/mL penicil-
lin (Gibco), 100 μg/mL streptomycin (Gibco), 10 μM
SB431542 (Wako), 100 nM LDN193189 (Wako),
20 ng/mL EGF (Peprotech), 20 ng/mL bFGF (Pepro-
tech)], and patient-derived iPSCs were maintained at
37 °C under humidified atmosphere of 5 % CO2.
Emergent NSCs were expanded in NSC induction
medium and were characterized by immunocytochem-
ical staining. Fluorophore-conjugated primary anti-
body used was 5 μg/mL AlexaFluor 488-conjugated
anti-Nestin (Millipore).
Directed differentiation of iPSCs into neural crest cells
(NCCs)
Directed differentiation of patient-derived iPSCs into
NCCs was performed according to a previous report
[25] with modifications: Briefly, patient-derived iPSCs
were seeded onto Geltrex-coated dishes and were main-
tained in mTeSR1 medium at 37 °C under humidified
atmosphere of 5 % CO2. After 3 days in adherent cul-
ture, culture medium was switched to NCC induction
medium [mTeSR1 medium (STEMCELL Technologies)
supplemented with 100 units/mL penicillin (Gibco),
100 μg/mL streptomycin (Gibco), 2 μM (2’Z,3’E)-6-
bromoindirubin-3’-oxime (Wako), 20 μM SB431542
(Wako)], and patient-derived iPSCs were maintained at
37 °C under humidified atmosphere of 5 % CO2. Emer-
gent NCCs were expanded in NCC induction medium
and were characterized by immunocytochemical stain-
ing. Fluorophore-conjugated primary antibody used was
5 μg/mL FITC-conjugated anti-HNK1 (Miltenyi Biotec).
Terminal differentiation of NSCs and NCCs into neurons
Terminal differentiation of patient-derived NSCs and
NCCs into neurons was performed as follows: Briefly,
patient-derived NSCs and NCCs were seeded at high cell
density onto Geltrex-coated 6-well culture plates and
were maintained at 37 °C under humidified atmosphere
of 5 % CO2. After 3 days in culture, culture medium was
switched to neuron induction medium [Neurobasal
medium (Gibco) supplemented with 1 × N2 (Gibco), 1 ×
B27 minus vitamin A (Gibco), 1 × GlutaMAX (Gibco),
100 units/mL penicillin (Gibco), 100 μg/mL strepto-
mycin (Gibco), 10 ng/mL BDNF (Peprotech), 10 ng/mL
GDNF (Peprotech), 10 ng/mL NGF (Peprotech), 500 μM
dbcAMP (Sigma), 200 μM ascorbic acid (Wako)], and
patient-derived NSCs and NCCs were maintained at 37 °C
under humidified atmosphere of 5 % CO2 for more than
2 weeks. For immunocytochemical detection of emergent
NSC-derived neurons, 5 μg/mL anti-TUJ1 (Abcam) and
2.5 μg/mL Alexa Fluor 568 (Molecular Probes) were used.
For immunocytochemical detection of emergent NCC-
derived neurons, 5 μg/mL PE-conjugated anti-Peripherin
(Santa Cruz) was used.
Results
Molecular pathomechanisms of mutant mitochondrial
tRNATrp
We found a patient who was clinically diagnosed as
MELAS with multiple organ involvement including
hypertrophic cardiomyopathy, acute pancreatitis, gastro-
intestinal malabsorption, renal tubular disturbance, and
endocrine glucose intolerance (Fig. 1a-d). We identified
a disease-causative mutation, m.5541C > T heteroplasmy
in MT-TW gene, in this patient (Fig. 1e and Additional
file 1: Table S1). Skeletal muscle tissues and the estab-
lished myoblasts showed quite high mutant proportions
(~100 %), whereas blood tissues showed relatively low
mutant proportions (~50 %). The same m.5541C > T
heteroplasmy was also observed in blood tissues from
this patient’s asymptomatic mother at quite low muta-
tion levels (~10 %). The mutated position in the
anticodon-stem of MT-TW gene was evolutionarily
conserved through most parts of primates and typical
eukaryotes (Fig. 1f ). We also performed in silico
calculation of mitochondrial tRNATrp stability for both
wild-type and m.5541C > T mutant (Additional file 1:
Figure S1). Mutant mitochondrial tRNATrp was destabi-
lized by m.5541C > T and was probably existed more
physicochemically stable but biochemically inappropriate
conformation. Our findings suggest that m.5541C > T
presumably induces defects in mitochondrial tRNATrp-
associated translation machinery.
Although m.5541C > T was previously reported and
predicted as "definitely pathogenic" [26], and our patient
was the second case to show this mutation, the detailed
molecular pathomechanisms of m.5541C > T —how this
mutation influences mitochondrial pathophysiology,
which is closely related to the variation and the severity
of clinical symptoms in affected individuals— remain
unclear. We comprehensively evaluated mitochondrial
function using patient-derived myoblasts carrying quasi-
homoplasmic m.5541C > T (i.e., ~100 % mutant mtDNA
exists within a cell). On mitochondrial respiratory chain
complexes, severely decreased CIV activity and moder-
ately decreased CI activity were both detected in the pa-
tient, whereas the other respiratory chain complexes
showed within normal ranges (Fig. 2a,b). CIV holoen-
zyme and CIV-containing respiratory supramolecular ar-
chitectures were also diminished in the patient, whereas
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the other respiratory chain complexes showed almost
normal levels with the exception of moderately de-
creased CI holoenzyme amount (Fig. 2c,d). Such CIV
holoenzyme deficits in the patient were most likely be-
cause of decreased mRNA and protein expression levels
of mtDNA-encoded CIV structural subunits (Fig. 2e-g).
On mitochondrial physiology, widespread dysfunction
such as decreased ATP level, increased oxidative stress
level, and damaged membrane potential level were all
observed in the patient (Fig. 2h-j). We also performed
in silico prediction on mitochondrial tryptophan con-
tents and their locations in each mtDNA-encoded CIV
structural subunit (Additional file 1: Figure S2). Amino
acid sequences in all mtDNA-encoded CIV structural
subunits showed high homology between bovine and hu-
man, and bovine mitochondrial tryptophan residues
were predominantly located in α-helix and β-sheet do-
mains essential for the maintenance of CIV structural
subunit conformations. Some human mitochondrial
tryptophan residues in mtDNA-encoded CIV structural
subunits were also located at the boundary between CIV
structural subunits necessary for CIV holoenzyme as-
sembly. Our results clearly indicate that m.5541C > T
primarily induces the aberrant steady-state of mitochon-
drial respiratory chain complexes, followed by severely
injured mitochondrial homeostasis.
Cell-type-specific disease phenotypes of MELAS using
patient-derived iPSCs carrying all mutant mitochondrial
tRNATrp
We next generated each 3 lines of integration-free disease-
relevant iPSCs derived from myoblasts of both control and
the patient carrying quasi-homoplasmic m.5541C >T as in
vitro disease models. No apparent differences in embryonic
stem cell (ESC)-like pluripotent characteristics were con-
firmed between iPSCs derived from control and the patient
(Fig. 3 and Additional file 1: Figure S3). To elucidate
patient-specific cellular disease phenotypes triggered by
quasi-homoplasmic m.5541C >T, we used myotubes and
iPSC-derived neurons of both control and the patient
(Fig. 4a). In myogenic lineage, no significant differences in
in vitro differentiation propensity into ACTA1-positive
myotubes were observed between control and the patient
(Fig. 4b,c). This phenomenon indicates that m.5541C >T
seems not to affect skeletal muscle development in the
patient regardless of serious mitochondrial dysfunction
(see also Figs. 1d and 2). We differentiated patient-derived
iPSCs into central nervous system (CNS) lineage. Efficient
differentiation into nestin-positive NSCs (>95 % conver-
sion) was observed in both control and the patient (Fig. 4d,e
and Additional file 1: Figure S4a); however, the number
of TUJ1-positive mature CNS neurons was markedly
decreased only in the patient (Fig. 4f,g and Additional
file 1: Figure S4b), and most parts of patient-derived
differentiating NSCs finally died during long-term terminal
differentiation (data not shown). We also differentiated
patient-derived iPSCs into peripheral nervous system (PNS)
lineage. A trend quite similar to CNS lineage, stable differ-
entiation into HNK1-positive NCCs (>95 % conversion)
was confirmed in both control and the patient (Fig. 4h,i
and Additional file 1: Figure S4c); however, significant
decrease of peripherin-positive mature PNS neurons was
detected only in the patient (Fig. 4j,k and Additional file 1:
Figure S4d), and patient-derived differentiating NCCs no
longer survived during extended periods of neuronal mat-
uration (data not shown). Several recent studies have dem-
onstrated that mitochondria are gradually rejuvenated to an
ESC-like "quiescent state" during cellular reprogramming
[27–30]. Our results also suggest that stem/progenitor cells
of both CNS and PNS lineages are minimally influenced by
m.5541C >T, most likely because these cell types may pos-
sess a less active mitochondrial respiration state similar to
ESCs and iPSCs. Therefore, we conclude that the molecular
pathogenicity of m.5541C >T is strongly visible in termin-
ally differentiated post-mitotic neurons, but not their stem/
progenitor cells, which is probably associated with the
degree of mitochondrial maturation during cellular
lineage-commitment process.
Discussion
The molecular pathomechanisms of m.5541C > T can be
summarized as follows: This mutation firstly loses the
appropriate base pair interaction, from Watson-Crick to
T-G mismatching, in the anticodon-stem of MT-TW
gene and induces defects in mitochondrial tRNATrp-
associated translation machinery most likely due to
inadequate anticodon recognition of mitochondrial
tryptophan by its altered conformation. Mutant mito-
chondrial tRNATrp disturbs the synthesis of mtDNA-
encoded respiratory chain complexes subunits; in this
case, markedly decreased amounts of mtDNA-encoded
CIV subunits predominantly inhibit CIV holoenzyme
formation at each assembly process [31]. In fact, some
patients carrying this mutation or other reported patho-
genic mutations in the anticodon-stem of MT-TW gene
also present severe COX deficiency [8, 26, 32]. There-
fore, our findings clearly demonstrate why mutant
mitochondrial tRNATrp is able to cause severe COX
deficiency as one of common clinical phenotypes. In-
duced mitochondrial respiratory dysfunction triggered
by loss of CIV holoenzyme severely impairs mitochon-
drial biogenesis and bioenergetics such as decreased
ATP level, increased oxidative stress level, and damaged
membrane potential level. Increased oxidative stress
level may promote the accumulation of oxidative dam-
ages to other mitochondrial enzymes, substrates, lipids,
and mtDNA, all of which lead to premature cell senes-
cence. Damaged membrane potential level may also
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accelerate the leakage of cytochrome c molecules in
mitochondrial electron transport system, which induces
apoptotic cell death. Thus, m.5541C > T causes wide-
spread mitochondrial dysfunction, which is closely
related to cell-type-specific physiological impairment in
various post-mitotic tissues and organs in this patient.
This case is consistent with MELAS with multiple
organ involvement characterized by its various clinical
symptoms; however, we did not find any typical ab-
normalities in patient-derived skeletal muscle tissues
other than diffuse COX deficiency. Generally, 80-90 %
of MELAS patients those carrying mutant mtDNAs
(e.g., m.3243A > G in MT-TL1 gene) exhibit ragged-
red-fibers and/or strongly SDH-reactive blood vessels
in skeletal muscle tissues, which indicate morpho-
logical, numerical, and/or physiological abnormalities
in mitochondria. These findings suggest that quasi-
homoplasmic m.5541C > T may cause rare patho-
logical signatures in skeletal muscle development,
presumably because this patient exhibits no signifi-
cant differences in in vitro differentiation propensity
into terminally differentiated myotubes as compared
with control regardless of serious mitochondrial
dysfunction.
Recently, several groups have also reported iPSC-based
disease models for other heteroplasmic mutant mtDNAs
[33-37]. As the common perceptions, intracellular mu-
tant mtDNA proportions must always be considered for
actual in vitro recapitulation of mitochondrial diseases at
each cellular fate-determining process such as repro-
gramming, self-renewal, or differentiation. From this
viewpoint, we generated integration-free patient-derived
iPSCs carrying ~100 % mutant mtDNA and used them
as in vitro cellular disease models to investigate the de-
finitive genotype-phenotype relationship. We also dem-
onstrated that terminally differentiated iPSC-derived
CNS and PNS neurons, but not their stem/progenitor
cells, are strongly influenced by m.5541C>T, most likely
because the molecular pathogenic severity of mutant
mitochondrial tRNATrp may be determined by the de-
gree of physiological and morphological maturation in
mitochondria. Although our presenting results do not
completely elucidate the relationship between in vitro cellu-
lar disease phenotypes and in vivo clinical symptoms of this
patient, our approach would be widely available for under-
standing bona fide molecular pathomechanisms and
cellular pathophysiology of affected tissues and organs in
patients carrying heteroplasmic mtDNA mutations, as well
as for further drug discovery applications.
Conclusions
Throughout this study, we identified the "definite" mo-
lecular pathomechanisms of m.5541C>T and demon-
strated cell-type-specific in vitro disease phenotypes
triggered by mutant mitochondrial tRNATrp using inte-
gration-free disease-relevant iPSCs derived from myo-
blasts of the patient. Our iPSC-based strategy therefore
holds enormous promise for the development of evi-
dence-based, personalized diagnostics and therapeutics
to patients exhibiting various mitochondrial diseases.
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